-
公开(公告)号：US20220016042A1
公开(公告)日：2022-01-20
申请号：US17411591
申请日：2021-08-25
Applicant: Infectious Disease Research Institute
Inventor： Neal VAN HOEVEN , Traci MIKASA , Christopher B. FOX , Anwar AHNIYAZ , Mark T. ORR , Amit KHANDHAR
Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such a nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
-
公开(公告)号：US11135281B2
公开(公告)日：2021-10-05
申请号：US16315986
申请日：2017-07-07
Applicant: Hawaii Biotech Inc. , Infectious Disease Research Institute
Inventor： David E. Clements , Neal Van Hoeven
Abstract: A West Nile virus (WNV) vaccine for human use is described that contains a recombinantly produced form of truncated WNV envelope glycoprotein and a combination of a Toll-like receptor 4 (TLR-4) and saponin adjuvants. A pharmaceutically acceptable vehicle may also be included in the vaccine.
-
公开(公告)号：US10940198B2
公开(公告)日：2021-03-09
申请号：US16473393
申请日：2017-12-20
Inventor： Hyo Jung Nam , Eun Mi Kim , Duck Hyang Shin , Steven G. Reed , Kang Il Yoo , Sung Jun Hong
IPC: A61K39/25 , A61P31/22 , A61K31/7024 , A61K31/01 , A61K39/00 , A61K39/39 , G01N33/569
Abstract: The present invention relates to a herpes zoster vaccine composition, which comprises glycoprotein E of Varicella zoster virus, a glucopyranosyl lipid adjuvant, and a metabolic oil, and selectively increases a cell-mediated immune reaction without having disadvantages of attenuated live vaccines, thereby exhibit high safety and a high preventive effect against herpes zoster.
-
4.发明申请公开(公告)号：US20200338180A1
公开(公告)日：2020-10-29
申请号：US16333596
申请日：2017-09-15
Applicant: Infectious Disease Research Institute
Inventor： Steven G. REED , Malcolm S. Duthie
Abstract: Compositions and methods for preventing, treating and detecting leprosy are disclosed. The compositions generally comprise polypeptides comprising one or more Mycobacterium leprae antigens as well as polynucleotides encoding such polypeptides.
-
公开(公告)号：US20200230056A1
公开(公告)日：2020-07-23
申请号：US16622908
申请日：2018-06-15
Applicant: Infectious Disease Research Institute
Inventor： Christopher B. FOX , Amit Praful KHANDHAR , Neal VAN HOEVEN , Jesse H. ERASMUS , Susan S. LIN
Abstract: Provided herein are nanostructured lipid carrier compositions, and methods of making and using thereof. The compositions comprise a nanostructured lipid carrier (NLC), where the NLC comprises an oil core comprising a mixture of a liquid phase lipid and a solid phase lipid, a cationic lipid, a sorbitan ester, and a hydrophilic surfactant, and optionally a bioactive agent. The bioactive agent can be associated with the NLC. The compositions are capable of delivery of a biomolecule to a cell for the generation of an immune response, for example, for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the compositions and using the compositions for stimulating an immune response are also provided.
-
Patent Agency Ranking
公开(公告)号：US09907845B2
公开(公告)日：2018-03-06
申请号：US14096582
申请日：2013-12-04
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Darrick Carter
IPC: A61K39/395 , A61K39/39 , A61K9/107 , A61K39/00 , A61K39/35 , A61K45/06 , A61K39/008 , A61K39/04 , A61K39/145
CPC classification number: A61K39/39 , A61K9/107 , A61K39/0011 , A61K39/008 , A61K39/04 , A61K39/145 , A61K39/35 , A61K45/06 , A61K2039/55511 , A61K2039/55572 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/41 , Y02A50/491
Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
-
7.发明申请COMPOSITIONS AND METHODS FOR TREATING AN ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION 审中-公开用于治疗活动性MYCOBACTERIUM TUBCCOSOSIS感染的组合物和方法公开(公告)号：US20150182612A1
公开(公告)日：2015-07-02
申请号：US14419477
申请日：2013-08-02
Applicant: Infectious Disease Research Institute
Inventor： Steven G. Reed , Rhea N. Coler
CPC classification number: A61K39/04 , A61K31/4409 , A61K31/496 , A61K39/39 , A61K45/06 , A61K2039/545 , A61K2039/55511 , A61K2039/70 , A61K2300/00
Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
Abstract translation: 本公开涉及用于治疗活动性结核感染的方法和组合物，以及用于改善针对活动性结核感染的化疗方案的功效的方法和组合物。 本公开涉及治疗活动性结核分枝杆菌感染或由哺乳动物的潜伏感染的再活化引起的活性感染的方法以及提高针对活动性结核分枝杆菌感染的化学疗法疗效的方法。
-
8.发明申请公开(公告)号：US20150017200A1
公开(公告)日：2015-01-15
申请号：US14286647
申请日：2014-05-23
Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE
Inventor： Ajay BHATIA , Steven G. REED
IPC: C07K14/44 , G01N33/569 , C07K16/20
CPC classification number: C07K14/44 , A61K38/00 , A61K39/00 , C07K16/20 , G01N33/56905 , G01N33/6893 , Y10S435/81 , Y10S435/975
Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.
Abstract translation: 本发明一般涉及由包含源自利什曼原虫抗原K26，K39和K9的元件的合成基因构建体制成的融合蛋白。 融合蛋白特别可用于诊断利什曼病，特别是动物如人和狗中的内脏利什曼病。
-
9.发明申请ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME 审中-公开包含TLR4激动剂的补充剂配方及其使用方法公开(公告)号：US20150017191A1
公开(公告)日：2015-01-15
申请号：US14377488
申请日：2013-02-07
Applicant: Infectious Disease Research Institute
Inventor： Christopher Fox , Steven G. Reed , Susan Baldwin , Thomas Vedvick
Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
Abstract translation: 公开了制剂和方法，包括用于诱导或增强免疫应答的疫苗和药物组合物。 制剂通常包含浓度为约0.01％-1％v / v的TLR4激动剂和可代谢的油，其中乳液的疏水性：亲油平衡（HLB）大于约9。
-
公开(公告)号：US11173126B2
公开(公告)日：2021-11-16
申请号：US16098617
申请日：2017-05-31
Applicant: Infectious Disease Research Institute
Inventor： Neal Van Hoeven , Traci Mikasa , Christopher B. Fox , Anwar Ahniyaz , Mark T. Orr , Amit Khandhar
Abstract: Provided herein are nanoalum particles comprising an aluminum salt and a sizing agent, wherein the size of the particle ranges from about 1 nm to 450 nm. Such nanoalum particles are stable and are amenable to a terminal sterilization step prior to vialing. Compositions comprising the nanoalum particles, and the making and using of the nanoalum particles are also provided.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.027 seconds)
